As regards the deferral period for medical devices as defined in Article 1(4) of Regulation (EU) 2017/745 of the European Parliament and of the Council [Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p. 1).], taking into account concerns from the sector and some Member States on the estimated time for redesign steps, namely to find an alternative, to perform a qualification process and to seek registration of a newly designed mixture according to Regulation (EU) 2017/745, the Commission considers appropriate to grant a 7-year deferral period to these devices. Moreover, D4 and D5 may be found at concentrations above 0,1 % in some in vitro diagnostic devices (IVD) as defined in Article 1(2) of Regulation (EU) 2017/746 of the European Parliament and of the Council [Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176).]. As substitution in IVD presents similar concerns, it is appropriate to give these devices the same deferral period.
Recital 19, Regulation (EU) 2024/1328
In forcesince 16 May 2024
Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January…Law
Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 Novembe…Law
- celex=31990L0385
- celex=31993L0042
- celex=31998L0079
- num:eu=1990/385
- num:eu=1993/42